Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Rachel Slade"'
Autor:
Stephanie Burnett, Amit Bahl, Bruno Morgan, Lucy Tregellas, Lisa Pickering, Alastair Thomson, Emma Hall, Tony Elliott, Rachel Slade, Balaji Venugopal, Steve Nicholson, Naveen S. Vasudev, Holly Tovey, Clare Cruickshank, Peter Kirkbride, Alison Hassall, Anita Mitra
Publikováno v:
British Journal of Cancer
Background We investigated the first-line activity of vinflunine in patients with penis cancer. Cisplatin-based combinations are commonly used, but survival is not prolonged; many patients are unfit for such treatment or experience toxicity that outw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6709a5dc75da982f3b26a6c6831ed122
https://doi.org/10.1038/s41416-021-01574-9
https://doi.org/10.1038/s41416-021-01574-9
Autor:
Nina Tunariu, Pasquale Rescigno, Jonathan Welti, Lorna Leonard, Maryou B. Lambros, Niven Mehra, J.S. de Bono, Karen E Swales, Zafeiris Zafeiriou, Diletta Bianchini, Vasiliki Michalarea, D. Nava Rodrigues, Holly Tovey, Nuria Porta, Ruth Riisnaes, Stephen R. Plymate, Florence I. Raynaud, Rachel Slade, Ines Figueiredo, Adam Sharp, Udai Banerji, Penny Flohr, Joaquin Mateo, Susana Miranda, Ruth Ruddle, Michael Kolinsky, Emma Hall, Mateus Crespo, Jun Luo, Suzanne Carreira
Publikováno v:
Annals of Oncology
Annals of Oncology, 31, 619-625
Annals of Oncology, 31, 5, pp. 619-625
Annals of Oncology, 31, 619-625
Annals of Oncology, 31, 5, pp. 619-625
Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence suggests that combined inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2805a29633f5113e129c4cb31962d65
https://hdl.handle.net/2066/220752
https://hdl.handle.net/2066/220752
Autor:
Rachel Slade
A moving and eye-opening look at the story of manufacturing in America, whether it can ever successfully return to our shores, and why our nation depends on it, told through the experience of one young couple in Maine as they attempt to rebuild a los
Autor:
Rachel Slade
WINNER OF THE MAINE LITERARY AWARD FOR NON FICTIONNATIONAL BESTSELLERA NEW YORK TIMES NOTABLE BOOKAN NPR BEST BOOK OF THE YEARONE OF JANET MASLIN'S MUST-READ BOOKS OF THE SUMMERA NEW YORK TIMES EDITOR'S CHOICEONE OF OUTSIDE MAGAZINE'S BEST BOOKS OF T
Autor:
Lisa M. Pickering, Holly Tovey, Tony Elliott, Stephanie M. Burnett, Clare Cruickshank, Amit Bahl, Peter Kirkbride, Anita Mitra, Alastair H Thomson, Naveen Vasudev, Balaji Venugopal, Rachel Slade, Lucy Tregellas, Bruno Morgan, Alison Hassall, Emma Hall, Steve Nicholson
Publikováno v:
Journal of Clinical Oncology. 36:4514-4514
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::effcf7048d9188e8ca89d5c3b1b8b8a0
https://doi.org/10.1200/jco.2018.36.15_suppl.4514
https://doi.org/10.1200/jco.2018.36.15_suppl.4514
Autor:
Tony Elliott, Anita Mitra, Holly Tovey, Alastair Thomson, Steve Nicholson, Naveen S. Vasudev, Lucy Tregellas, Emma Hall, Stephanie Burnett, Lisa Pickering, Amit Bahl, Rachel Slade, Peter Kirkbride, Bruno Morgan, Alison Hassall
Publikováno v:
Journal of Clinical Oncology. 36:547-547
547 Background: Platinum-based combination chemotherapy regimens are used in the treatment of carcinoma of the penis, but toxicity limits their value for patients with metastatic disease. This trial aims to define both the toxicity and the rate of di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbd990d6924438b823adea8184f9dec9
https://doi.org/10.1200/jco.2018.36.6_suppl.547
https://doi.org/10.1200/jco.2018.36.6_suppl.547
Autor:
Udai Banerji, Holly Tovey, Rachel Slade, Joaquin Mateo, Penelope Flohr, Johann S. de Bono, Niven Mehra, Lorna Leonard, Mateus Crespo, Pasquale Rescigno, Florence I. Raynaud, Karen E Swales, Nuria Porta, Diletta Bianchini, Ruth Riisnaes, Nina Tunariu, Emma Hall, Michael Kolinsky, Zafeiris Zafeiriou, Ines Figueiredo
Publikováno v:
Journal of Clinical Oncology. 35:135-135
135 Background: Activation of the PI3K/AKT/mTOR pathway may contribute to resistance to androgen receptor targeted therapies in metastatic CRPC (mCRPC). The phase I/II RE-AKT trial (NCT02525068) investigates the safety and activity of enzalutamide (e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03c583c6b05c240eecd49af40dbf2720
https://doi.org/10.1200/jco.2017.35.6_suppl.135
https://doi.org/10.1200/jco.2017.35.6_suppl.135